Roswell Park

Company

Roswell Park develops one asset, in phase 2 (SurVaxM in glioblastoma). Mostly vaccine acting on apoptosis and BIRC5.

Assets
1
Furthest
Phase 2
Grants
3
Trials
0
Signals
5

Pipeline

1

  • SurVaxM

    Vaccine targeting survivin (BIRC5) to stimulate an anti-tumor immune response.

    Phase 2VaccineApoptosisBIRC5glioblastomanewly diagnosed glioblastomaPartner

Full company profiles: pipeline, trials, funding and people.

See Pro
  • Evidence behind the mechanisms1
  • People7
  • Signals6
  • Integrity notices10
  • Similar companies3

Updated 7 Oct 2026 · 2 sources

Intelligence